Sector ratings Formycon AG

Equities

Market Closed - Xetra Other stock markets 16:35:19 12/02/2026 GMT			After hours 19:44:37
23.60 ^EUR	-1.46%		23.68	+0.32%

02-11	Formycon, Lotus Sign License Deal for Keytruda Biosimilar in Asia-Pacific Region	MT
02-11	Swiss stocks - Factors to watch on February 11	RE

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Financial revisions	Global Valuation	Visibility	Consensus
FORMYCON AG	502M	-	B	-		-
LONZA GROUP AG	46.14B		AAA
BEONE MEDICINES AG	38.87B		-
CELLTRION, INC.	36.18B		A
IQVIA HOLDINGS INC.	30.05B		AAA
REVOLUTION MEDICINES, INC.	18.94B	-	B	-		-
EUROFINS SCIENTIFIC SE	13.55B		AA
ASCENDIS PHARMA A/S	13.6B	-	-	-		-
IONIS PHARMACEUTICALS, INC.	13.66B	-	A	-		-
REGENCELL BIOSCIENCE HOLDINGS LIMITED	13.21B	-	-	-	-	-	-	-
MEDPACE HOLDINGS, INC.	12.03B		BBB
ICON PUBLIC LIMITED COMPANY	10.17B		AA
QIAGEN N.V.	10.52B		AAA
BIO-TECHNE CORPORATION	9.93B		A
TEMPUS AI, INC.	9.54B	-	A	-		-
ABIVAX	9.07B	-	BBB	-		-
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	8.17B		A
PRAXIS PRECISION MEDICINES, INC.	8.97B	-	B	-		-
BLUEPRINT MEDICINES CORPORATION	8.38B	-	BB	-		-	-	-
HANGZHOU TIGERMED CONSULTING CO., LTD	7.77B		AAA
Average	15.96B		A
Weighted average by Cap.			A